Distal and proximal colon cancers differ in terms of molecular,
pathological, and clinical features

J 2014

Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features

MISSIAGLIA, E.; B. JACOBS; G. D´ARIO; A.F. DI NARZO; C. SONESON et al.

Základní údaje

Originální název

Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features

Autoři

MISSIAGLIA, E.; B. JACOBS; G. D´ARIO; A.F. DI NARZO; C. SONESON; Eva BUDINSKÁ; Vlad POPOVICI; L. VECCHIONE; S. GERSTER; P. YAN; Arnaud ROTH; D. KLINGBIEL; F.T. BOSMAN; M. DELORENZI a S. TEJPAR

Vydání

Annals of Oncology, Oxford, Oxford University Press, 2014, 0923-7534

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 7.040

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/14:00076812

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Colon cancer; Expression profiling; Mutations; Oncogenic pathways; Survival

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 4. 2015 13:44, Soňa Böhmová

Anotace

V originále

Background Differences exist between the proximal and distal colon in terms of developmental origin, exposure to patterning genes, environmental mutagens and gut flora. Little is known on how these differences may affect mechanisms of tumorigenesis, side specific therapy response or prognosis. We explored systematic differences in pathway activation and their clinical implications. Materials and Methods Detailed clinico-pathological data for 3045 colon carcinoma patients enrolled in the PETACC3 adjuvant chemotherapy trial were available for analysis. A subset of 1404 samples had molecular data, including gene expression and DNA copy number profiles for 589 and 199 samples, respectively. In addition, 413 colon adenocarcinoma from TCGA collection were also analyzed. Tumor side effect on anti-EGFR therapy was assessed in a cohort of 325 metastatic patients. Outcome variables considered were relapse-free survival (RFS) and survival after relapse (SAR). Results Proximal carcinomas were more often mucinous, MSI-high, mutated in key tumorigenic pathways, expressed a BRAF-like and a serrated pathway signature, regardless of histological type. Distal carcinomas were more often chromosome instable and EGFR or HER2 amplified, and more frequently over-expressed epiregulin. While risk of relapse was not different per side, survival after relapse was much poorer for proximal than for distal stage III carcinomas in a multivariable model including BRAF mutation status (N=285; HR=1.95 95% CI(1.6-2.4) P<0.001). Only patients with metastases from a proximal carcinoma responded to anti-EGFR therapy, in line with the predictions of our pathway enrichment analysis. Conclusions Colorectal carcinoma side is associated with differences in key molecular features, some immediately druggable, with important prognostic effects which are maintained in metastatic lesions. Although within side significant molecular heterogeneity remains, our findings justify stratification of patients by side for retrospective and prospective analysis of drug efficacy and prognosis.

Citovat

MISSIAGLIA, E.; B. JACOBS; G. D´ARIO; A.F. DI NARZO; C. SONESON; Eva BUDINSKÁ; Vlad POPOVICI; L. VECCHIONE; S. GERSTER; P. YAN; Arnaud ROTH; D. KLINGBIEL; F.T. BOSMAN; M. DELORENZI a S. TEJPAR. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Annals of Oncology. Oxford: Oxford University Press, 2014, roč. 25, č. 10, s. 1995-2001, 8 s. ISSN 0923-7534. Dostupné z: https://doi.org/10.1093/annonc/mdu275.

@article{1202576,
   author = {Missiaglia, E. and Jacobs, B. and D´Ario, G. and Di Narzo, A.F. and Soneson, C. and Budinská, Eva and Popovici, Vlad and Vecchione, L. and Gerster, S. and Yan, P. and Roth, Arnaud and Klingbiel, D. and Bosman, F.T. and Delorenzi, M. and Tejpar, S.},
   article_location = {Oxford},
   article_number = {10},
   doi = {https://doi.org/10.1093/annonc/mdu275},
   keywords = {Colon cancer; Expression profiling; Mutations; Oncogenic pathways; Survival},
   language = {eng},
   issn = {0923-7534},
   journal = {Annals of Oncology},
   title = {Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features},
   volume = {25},
   year = {2014}
}

TY  - JOUR
ID  - 1202576
AU  - Missiaglia, E. - Jacobs, B. - D´Ario, G. - Di Narzo, A.F. - Soneson, C. - Budinská, Eva - Popovici, Vlad - Vecchione, L. - Gerster, S. - Yan, P. - Roth, Arnaud - Klingbiel, D. - Bosman, F.T. - Delorenzi, M. - Tejpar, S.
PY  - 2014
TI  - Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
JF  - Annals of Oncology
VL  - 25
IS  - 10
SP  - 1995-2001
EP  - 1995-2001
PB  - Oxford University Press
SN  - 09237534
KW  - Colon cancer
KW  - Expression profiling
KW  - Mutations
KW  - Oncogenic pathways
KW  - Survival
N2  - Background Differences exist between the proximal and distal colon in terms of developmental origin, exposure to patterning genes, environmental mutagens and gut flora. Little is known on how these differences may affect mechanisms of tumorigenesis, side specific therapy response or prognosis. We explored systematic differences in pathway activation and their clinical implications. Materials and Methods Detailed clinico-pathological data for 3045 colon carcinoma patients enrolled in the PETACC3 adjuvant chemotherapy trial were available for analysis. A subset of 1404 samples had molecular data, including gene expression and DNA copy number profiles for 589 and 199 samples, respectively. In addition, 413 colon adenocarcinoma from TCGA collection were also analyzed. Tumor side effect on anti-EGFR therapy was assessed in a cohort of 325 metastatic patients. Outcome variables considered were relapse-free survival (RFS) and survival after relapse (SAR). Results Proximal carcinomas were more often mucinous, MSI-high, mutated in key tumorigenic pathways, expressed a BRAF-like and a serrated pathway signature, regardless of histological type. Distal carcinomas were more often chromosome instable and EGFR or HER2 amplified, and more frequently over-expressed epiregulin. While risk of relapse was not different per side, survival after relapse was much poorer for proximal than for distal stage III carcinomas in a multivariable model including BRAF mutation status (N=285; HR=1.95 95% CI(1.6-2.4) P<0.001). Only patients with metastases from a proximal carcinoma responded to anti-EGFR therapy, in line with the predictions of our pathway enrichment analysis. Conclusions Colorectal carcinoma side is associated with differences in key molecular features, some immediately druggable, with important prognostic effects which are maintained in metastatic lesions. Although within side significant molecular heterogeneity remains, our findings justify stratification of patients by side for retrospective and prospective analysis of drug efficacy and prognosis.
ER  -

MISSIAGLIA, E.; B. JACOBS; G. D´ARIO; A.F. DI NARZO; C. SONESON; Eva BUDINSKÁ; Vlad POPOVICI; L. VECCHIONE; S. GERSTER; P. YAN; Arnaud ROTH; D. KLINGBIEL; F.T. BOSMAN; M. DELORENZI a S. TEJPAR. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. \textit{Annals of Oncology}. Oxford: Oxford University Press, 2014, roč.~25, č.~10, s.~1995-2001, 8 s. ISSN~0923-7534. Dostupné z: https://doi.org/10.1093/annonc/mdu275.

Přehled o publikaci